Keywords: sciclone, sigma-tau, report, promising, ph, iii, zadaxin
SciClone and Sigma-Tau report promising Ph III Zadaxin data
Article | 18 February 2008
The USA's SciClone Pharmaceuticals and Italy-based Sigma-Tau SpA reported promising blinded interim data from a large, randomized Phase III clinical ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
